Back to the Top
The following message was posted to: PharmPK
Dear colleagues,
FDA guidance for conducting DDI studies does not recommend
a specific design. Both randomized crossover (S followed by S+I, S+I
followed
by S) and one-sequence crossover (S always followed by S+I or the
reverse) have
been used. Which design would be superior for a mechanism-based
inhibitor?
Many thanks, Rostam
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "DDI study" as the subject | Support PharmPK by using the |
Copyright 1995-2011 David W. A. Bourne (david@boomer.org)